Related Experiment Videos
Complement factors and acute phase reactants in the Guillain-Barré syndrome
Insights
Complement component levels (C3, C4) may predict Guillain-Barré syndrome severity. Higher acute phase concentrations of C3, C4, and orosomucoid correlate with worse outcomes and residual weakness in patients.
Area of Science:
- Immunology
- Neurology
Background:
- Guillain-Barré syndrome (GBS) is an autoimmune disorder affecting peripheral nerves.
- Complement system activation is implicated in GBS pathogenesis.
- Predictive biomarkers for GBS severity and prognosis are needed.
Purpose of the Study:
- To investigate the relationship between complement component concentrations and GBS severity.
- To assess the prognostic value of C3, C4, and orosomucoid levels in GBS patients.
Main Methods:
- Serum concentrations of C3, C4, C1 inactivator, C3 proactivator, and orosomucoid were measured in 13 GBS patients.
- Patients were categorized based on disease severity (mild vs. severe).
- Correlation between complement levels and clinical outcomes (residual weakness) was analyzed.
Main Results:
- Severely affected GBS patients exhibited higher acute phase levels of C3, C4, and orosomucoid compared to mildly affected patients.
- Mildly affected patients showed complement concentrations within the upper normal range.
- Higher initial C3, C4, and orosomucoid levels were associated with a greater likelihood of developing residual weakness.
Conclusions:
- Serum concentrations of C3 and C4 may serve as early indicators of GBS severity.
- Complement component levels, particularly C3 and C4, could aid in predicting prognosis in the acute phase of Guillain-Barré syndrome.
Abstract:
The concentrations of C3, C4, C1 inactivator, C3 proactivator and orosomucoid were determined in sera from 13 patients with Guillain-Barré syndrome. The most severely affected patients had the highest levels of C3, C4 and orosomucoid in the acute phase with a slight decline over the following 3-8 weeks. The mildly affected patients had complement concentrations in the upper normal range. In the group of patients with the highest concentrations of C3, C4 and orosomucoid, 4 out of 6 developed residual weakness, while residual weakness was only found in 1 out of 7 with normal concentrations. The measurement of C3 and C4 may, therefore, be of value in estimating the severity and prognosis in the early phase of the disease.